FM
fazen.markets
healthcare·esfritzh

Lantern Pharma Q3 2026: Loss Widens to $5.4M, Cash $7.6M

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

lantern-pharmaltrn-stockbiotech-earningsgoing-concernai-oncology
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Lantern Pharma's headline profit masks a $5.4 million operating loss and a going-concern warning on $7.6 million of cash.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Lantern Pharma Inc. (NASDAQ: LTRN) reported a third-quarter 2026 loss from operations of approximately $5.4 million and closed the period with roughly $7.6 million in cash, cash equivalents and marketable securities, the clinical-stage AI-driven precision oncology company announced on November 18, 2026. The quarter included a $2.0 million accrual tied to a proposed settlement with a former part-time consultant; excluding that accrual, operating loss was approximately $3.4 million. The company also disclosed that its cash position is not sufficient to fund operations for the next 12 months.

Context — why the quarter matters for LTRN

The report frames the quarter around a financing, a leadership change and several clinical milestones. Lantern closed a registered direct offering and concurrent private placement on September 30, 2026, raising gross proceeds of approximately $4.0 million before offering expenses of about $0.4 million. That capital arrived at the end of the quarter, so the $7.6 million balance reflects it.

The comparable period the company itself cites is the third quarter of 2025, when operating loss was approximately $4.3 million and cash, cash equivalents and marketable securities stood at roughly $10.1 million as of December 31, 2025. The direction of travel is lower liquidity against a wider reported loss.

What changed to trigger the disclosure now is the combination of the September financing, the November leadership transition and the proposed settlement. Panna Sharma resigned as President, Chief Executive Officer and board member on November 15, 2026, and the Board appointed Chief Financial Officer David Margrave as Interim CEO effective November 16, 2026, with a search for a permanent successor to begin promptly.

The company also said it intends to pursue periodic capital raises, including potential sales under its ATM facility, as well as collaborations, grant funding and other opportunities to extend its operating runway. Those are forward-looking statements and remain the company's expectations, not confirmed transactions.

Data — what the numbers show

The financial picture is defined by a small cash base, a reduced research budget and a one-off legal charge. R&D expenses fell to approximately $1.6 million in Q3 2026 from approximately $2.4 million a year earlier, a decline of about $0.87 million, or 36%. The company attributed the drop mainly to roughly $0.69 million less in research studies and materials costs tied to its clinical trials.

General and administrative expenses rose to approximately $3.8 million from approximately $1.9 million, an increase of about $1.9 million, or 99%. The $2.0 million settlement accrual drove most of that. Excluding the accrual, G&A was approximately $1.8 million, down about 5% year over year.

MetricQ3 2026Q3 2025
R&D expense~$1.6M~$2.4M
G&A expense~$3.8M~$1.9M
Operating loss~$5.4M~$4.3M
Net income (loss)~$0.7M~$(4.2)M

Net income was approximately $0.7 million, or $0.05 per basic share, versus a net loss of approximately $4.2 million, or $0.39 per share, a year earlier. The swing came from a non-cash gain: the fair value of May 2026 investor and placement agent warrants fell by approximately $6.0 million during the quarter, primarily on a lower stock price. The warrant liability was approximately $1.5 million as of September 30, 2026. Shares outstanding were 14,935,576.

Analysis — what it means for markets and sectors

The gap between the reported net income and the operating loss is the central analytical point. A $6.0 million non-cash warrant remeasurement gain can flip a loss-making biotech to a headline profit without any cash entering the business. Investors reading only the bottom line would miss that operating loss was approximately $5.4 million and that the company itself flagged substantial doubt about its ability to continue as a going concern absent substantial additional funding.

The clinical pipeline is the offsetting asset. Lantern said the first clinical site completed core start-up milestones for a Phase 1b/2 trial in triple-negative breast cancer, a program that holds FDA Fast Track designation. In Taiwan, the TFDA approved the amended HARMONIC protocol and the lead site received IRB approval on September 29, 2026, opening Part 2 of the LP-300 study in L858R never-smoker NSCLC. Phase 1a glioblastoma data for LP-184 were published in the October 2026 issue of Cancer Research Communications.

A limitation worth weighing: those trial readouts are early. The company described the HARMONIC progression-free survival figure of 8.9 months across nine patients as preliminary, exploratory and based on small patient numbers. Clinical-stage oncology names with sub-$10 million cash and going-concern language typically trade on financing risk rather than pipeline optionality until a partner or raise closes.

Positioning follows that logic. Flow in names like this tends to run toward dilution-tolerant holders and event-driven traders, while longer-horizon funds wait for either a partnership or a capital raise to reset the runway. The company said it is exploring regional licensing, partnering and co-development opportunities for LP-300.

Outlook — what to watch next

The company gave specific near-term markers. It anticipates IRB approval at two additional Taiwan sites during the fourth quarter of 2026, which would broaden enrollment for HARMONIC Part 2. The planned Phase 1b/2a trial of LP-184 plus spironolactone in glioblastoma, sponsored by subsidiary Starlight Therapeutics under an FDA-cleared IND, remains subject to obtaining additional funding.

The bladder cancer trial at Rigshospitalet in Copenhagen is open for enrollment and prescreening patients. The proposed $2.0 million settlement is not yet finalized or effective, and the company said its estimate could change in the near term and any change may be material.

On the balance sheet, the practical catalyst is capital. The company said it will pursue periodic raises, including potential ATM sales. Any equity issuance at current levels would be the event that resets the going-concern question one way or the other.

Frequently Asked Questions

Why did Lantern Pharma report net income but a larger operating loss?

The difference is accounting, not operations. Lantern's May 2026 warrants are carried as liabilities and remeasured each quarter. A roughly $6.0 million decrease in their fair value, driven mainly by a lower share price, produced a non-cash gain that lifted net income to approximately $0.7 million. Operating loss, which excludes that item, was approximately $5.4 million.

What is the $2.0 million settlement accrual about?

Lantern said it reached an agreement in principle in November 2026 with a former part-time consultant who asserted disability discrimination, sexual harassment and related claims. Under the proposed terms the company would pay $2.0 million: $1.0 million within 30 days of effectiveness and $1.0 million later, tied to a funding threshold or the two-year anniversary. The settlement is not yet finalized.

Does Lantern Pharma have enough cash to operate?

The company said its cash, cash equivalents and marketable securities as of its Q3 2026 Form 10-Q are not sufficient to fund operations at the current level for the next 12 months, and it disclosed substantial doubt about its ability to continue as a going concern without substantial additional funding. It ended the quarter with approximately $7.6 million.

Bottom Line

Lantern Pharma's headline profit masks a $5.4 million operating loss and a going-concern warning on $7.6 million of cash.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related